Author: Ravi Shankar

• Intravenous SCY-247 was generally well tolerated in healthy participants, with no drug-related serious adverse events
• Once-daily intravenous doses of 50 mg or higher achieved exposures at or above the target identified in murine models of invasive candidiasis
• Company expects to initiate Phase 2 development of SCY-247 in oral and IV formulations in 2027, subject to regulatory agreement
• SCY-247 development is advancing with the support of a BARDA contract providing up to approximately $214 million in non-dilutive funding if milestones are achieved

JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of the intravenous (IV) formulation of SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate. SCY-247 is under development in both oral and intravenous (IV) formulations for the treatment and prevention of invasive fungal infections with the potential to provide therapeutic advantages by having activity against drug-resistant fungi.

“With Phase 1 studies of both the intravenous and oral formulations of SCY-247 now complete, we can refine our plans for the next stage of development of this second-generation fungerp, designed to address the growing threat of antimicrobial resistance,” said Todd Minga, M.D., SVP of Research and Development at Scynexis. “Having both intravenous and oral formulations could provide flexibility in managing patients with invasive candidiasis and those at risk of invasive fungal diseases. We look forward to initiating a Phase 2 study next year, subject to agreement with the FDA.”

Recently, Scynexis was awarded a BARDA contract (75A50126C00007) providing up to approximately $214 million in non-dilutive funding, if milestones are achieved, to advance the development of SCY-247. The award is structured as a cost-share arrangement, with BARDA providing support for eligible SCY-247 costs. The Company expects to fund its share of near-term program costs for SCY-247 within its existing operating plan. The Company’s previously communicated development plans for SCY-770 to initiate a Phase 2 study in the fourth quarter of 2026 and the Company’s projected cash runway into 2029 remain unchanged.

Phase 1 Study Results

The study evaluated the safety and characterized the pharmacokinetics of intravenous SCY-247 to inform progression to, and dose selection for, a Phase 2 study in patients with invasive candidiasis. The Phase 1 study enrolled 56 healthy participants across seven cohorts: 42 received SCY-247 by peripheral intravenous infusion and 14 received placebo. The study evaluated single ascending doses up to 300 mg and multiple ascending doses administered once daily for seven days up to 200 mg.

SCY-247 administered by peripheral intravenous infusion was generally well tolerated. The most commonly reported adverse reactions were mild to moderate erythema and pain at the infusion site. There were no drug-related serious adverse events or discontinuations due to a related adverse event.

Intravenous doses of 50 mg once daily or higher achieved exposures at or above the efficacy target identified in murine models of invasive candidiasis (AUC_0–24 of 20 µg·h/mL). A previously completed Phase 1 study indicated that oral doses of 100 mg or higher are also anticipated to achieve the target exposure for efficacy. Overall, the safety, tolerability, and pharmacokinetic profile observed in this study support the continued clinical development of SCY-247. Further details of the results from this study will be presented at an upcoming scientific meeting.

Invasive candidiasis is associated with high mortality, and resistance to the limited available antifungal options is making treatment increasingly challenging. Designed to address these limitations, SCY-247 has demonstrated in vitro and in vivo activity against several challenging Candida strains, including Candida auris, as well as most azole- and echinocandin-resistant strains. SCY-247 has been granted Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track designations by the U.S. Food and Drug Administration.

Future activities for this project may be funded in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Center for the Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50126C00007.

About SCY-247

SCY-247 is a second-generation triterpenoid (fungerp) antifungal candidate being developed for the treatment of invasive candidiasis and the prevention of invasive fungal diseases. As a member of a novel structural class, SCY-247 has a differentiated mechanism of action from existing antifungal classes and has demonstrated in vitro activity against a broad range of fungal pathogens, including strains resistant to currently available therapies. SCY-247 has been granted Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track designations by the U.S. Food and Drug Administration. Recently, Scynexis was awarded a BARDA contract (75A50126C00007) providing up to approximately $214 million in non-dilutive funding to advance the development of SCY-247.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: the Company’s expectation to initiate Phase 2 development of SCY-247 in oral and IV formulations in 2027, subject to regulatory agreement; the potential for SCY-247 to provide therapeutic advantages of both an oral and IV formulation; the amount and timing of any BARDA funding (under contract 75A50126C00007);   the Company’s expectation to fund its share of near-term program costs for SCY-247 within its existing operating plan; the anticipated initiation of the SCY-770 Phase 2 study in Q4 of 2026; the statements concerning the Company’s cash runway into 2029, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products, including the risk that SCYNEXIS may not reach alignment with the FDA on the planned Phase 2 study designs on the anticipated timelines or at all, and the risk that BARDA does not exercise one or more options under the BARDA contract (75A50126C00007). For the Company, this includes the future prospects of the Company’s SCY-247 and SCY-770 programs, the timing and results of the Company’s anticipated Phase 2 clinical studies, stock price volatility and uncertainties relating to the financial markets, the medical community and the global economy, and the impact of instability in general business and economic conditions, including changes in inflation and interest rates. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation, its most recent Annual Report on Form 10-K filed on March 4, 2026, including under the caption “Risk Factors,” and in other filings the Company makes with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: 
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com

Approximately 22-day field program to be managed by Lonquist, with results to feed 3D gravity inversion and 2D modelling along key seismic profiles

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has secured the approvals, permits and land access permissions required to commence its planned ground gravity survey at the Robinsons River Salt Project in Newfoundland and Labrador. The current survey design comprises approximately 500 planned measurement stations, with field acquisition expected to be undertaken by McKeown Exploration Services under the management of Lonquist Field Service (Canada), ULC (“Lonquist”). The survey will target gaps in existing gravity coverage and areas of exploration interest across the Project, including areas west of the Cloverleaf target and within the eastern block. Planned stations include traverses along selected historical seismic lines, allowing the new gravity measurements to be evaluated alongside existing seismic interpretations. Field acquisition is estimated to require approximately 22 working days, with final station locations and timing subject to access, weather and ground conditions, and completion of contractor arrangements.

The Mineral Lands Division of Newfoundland and Labrador’s Department of Energy and Mines approved the proposed geophysical survey program through Letter of Acceptance E260510, dated October 16, 2026. The survey will be conducted in accordance with the letter’s conditions, including in regard to environmental protection and archaeological requirements.

The Company aims to compare the new measurements with the Project’s historical airborne gravity-gradiometry data to assess consistency between the datasets, with the goal of improving confidence in the subsurface interpretation. The Company is planning to subsequently complete a modelling program that would include three-dimensional gravity inversion and targeted two-dimensional modelling along key seismic profiles near potential drilling locations. This work is intended to refine the interpretation of prospective salt structures and support decisions on future exploration drilling.

“We now have a detailed survey plan that builds directly on the technical work completed at Robinsons River,” said Paul Sparkes, Chief Executive Officer of Vortex. “These additional measurements will help us better understand the priority target areas and make more informed decisions about where to focus the next phase of exploration.”

The program advances the ground gravity survey announced on September 3, 2026, and Lonquist’s engagement announced on September 14, 2026. Vortex will provide further updates as fieldwork progresses. Gravity interpretations are non-unique and require integration with geological and drilling information; gravity data alone cannot establish salt composition, thickness or continuity.

Figure 1. Planned ground gravity station locations relative to the Robinsons River project licences and historical seismic lines. Station locations remain subject to field conditions and access.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Jared Suchan, Ph.D., P.Geo., Vice President of Exploration of the Company and a “Qualified Person” as defined by National Instrument 43-101.

For additional information concerning the Project and the Company’s data-verification and quality-assurance procedures, readers are referred to the Company’s technical report entitled Independent Technical Report on the Robinsons River Salt Property, dated July 31, 2023, available under the Company’s profile on SEDAR+.

About Vortex Energy Corp.

Vortex Energy Corp. is an exploration stage company engaged principally in the acquisition, exploration, and development of mineral properties in North America. The Company is currently advancing its Robinson River Salt Project comprised of a total of 942 claims covering 23,500 hectares located approximately 35 kilometres south of the town of Stephenville in the Province of Newfoundland & Labrador. The Robinson River Salt Project is prospective for both salt and hydrogen salt cavern storage. The Company is also currently advancing its Fire Eye Uranium Property in the Athabasca Basin, a region renowned for its uranium deposits.

On Behalf of the Board of Directors

Paul Sparkes

Chief Executive Officer, Director

+1 (778) 819-0164

info@vortexenergycorp.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information relates to future events or future performance and reflects management’s current expectations or beliefs regarding future events. Forward-looking information is often identified by words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “should”, “will” and similar expressions, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. In particular, this press release contains forward-looking information regarding, among other things: the commencement, conduct, scope, timing and completion of the planned ground gravity survey at the Robinsons River Salt Project (the “Project”); the number and final locations of measurement stations; the engagement, availability and performance of Lonquist Field Service (Canada), ULC and McKeown Exploration Services; the Company’s ability to satisfy the conditions of applicable approvals and permits and obtain and maintain required land access; the anticipated duration of field acquisition; the collection, processing, interpretation and integration of new gravity measurements with historical airborne gravity-gradiometry, seismic, geological and drilling information; the completion of three-dimensional gravity inversion and targeted two-dimensional modelling; the ability of the survey and modelling to improve confidence in subsurface interpretations, refine prospective salt structures and support the selection of potential drilling locations and decisions regarding future exploration drilling; and the provision of further updates as fieldwork progresses. 

Forward-looking information is based on assumptions that management considers reasonable as of the date of this press release, including, without limitation, assumptions that: the Company will have sufficient financial, technical and personnel resources to carry out the planned program; contractor arrangements will be completed and the contractors will be available and perform as anticipated; all required approvals, permits and land access permissions will remain in good standing and their conditions will be satisfied; field access, weather and ground conditions will permit the survey to proceed substantially as planned; the planned stations can be surveyed and reliable data can be collected, processed and interpreted; historical datasets are sufficiently accurate, complete and compatible for the contemplated comparisons and modelling; the survey and modelling will generate information useful for refining the Company’s geological interpretation and future exploration planning; and there will be no material adverse change in applicable laws, regulatory requirements, commodity or capital-market conditions, or the Company’s business and financing plans. 

Although management believes that the assumptions and expectations reflected in such forward-looking information are reasonable, there can be no assurance that they will prove to be correct. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such information. These risks and uncertainties include, without limitation: the survey may be delayed, modified, suspended or not completed due to contractor availability or performance, access restrictions, weather, ground conditions, equipment failure, safety or logistical issues, cost escalation, financing constraints, regulatory requirements or other circumstances; approvals, permits or land access permissions may be amended, suspended, revoked or subject to additional conditions; final station locations, survey coverage and timing may differ from those currently contemplated; collected data may be incomplete, inconsistent, of insufficient quality or incapable of being integrated with historical datasets; gravity interpretations are non-unique and may not accurately identify the geometry, composition, thickness, continuity or economic significance of subsurface features; the contemplated inversion and modelling may not be completed, may produce inconclusive or unexpected results, or may not identify suitable drilling targets; historical exploration information may be inaccurate, incomplete or not independently verifiable; exploration results may not support further work, drilling or development; future exploration programs may not be approved, financed or completed; costs may exceed estimates; and risks inherent in mineral exploration and development, including geological uncertainty, environmental and archaeological requirements, community and stakeholder considerations, changes in laws or regulatory requirements, and the availability of capital, personnel, equipment and services. Additional risks are described in the Company’s continuous disclosure filings available under its profile on SEDAR+. Readers are cautioned that the foregoing list is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Readers should not place undue reliance on forward-looking information. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. 

The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this press release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b3a03ba2-9c45-437c-ba72-32cb85aeff53

STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report third quarter 2026 financial results before the market opens on Thursday November 5, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.

Conference Call Information 
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2026 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system (CNS) and pain conditions.  Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.    

With a portfolio of differentiated ADHD medications, anchored by JORNAY PM^® (methylphenidate HCl) CII and AZSTARYS^® (serdexmethylphenidate and dexmethylphenidate) CII, and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives.  

For more information, please visit collegiumpharma.com or find us on LinkedIn.   

Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com

Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com

WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer section should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com

The company’s L-Series timing devices are designed to scale between COTS and traditional space-grade solutions, offering shorter lead times at competitive price points

CHANDLER, Ariz., Oct. 22, 2026 (GLOBE NEWSWIRE) — Microchip Technology (Nasdaq: MCHP) today announces the expansion of its L-Series of timing devices with the launch of its LX-820 Radiation-Tolerant Quartz Oscillator, designed for Low Earth Orbit (LEO) and other space applications. The L-Series portfolio provides satellite developers with a wide range of oscillator architectures to select from, each with varying frequency stability, phase noise, power and size, catering to different mission requirements.

The L-Series is positioned between commercial off-the-shelf (COTS) oscillators and traditional high-reliability space products, combining commercial- or military-grade components with production inspection, electrical and thermal analysis and hybrid manufacturing. The L-Series oscillators have passed Total Ionizing Dose (TID) and Single-Event Latchup (SEL) testing as complete, functioning devices, with radiation tolerance up to 50 krad and SEL testing to 40 MeV·cm²/mg. Additionally, most L-Series products also use swept quartz to reduce radiation-induced frequency drift. The L-Series OCXOs incorporate ruggedized construction and four-point crystal mounts designed to survive launch and the intended mission profile.

Designed to address two persistent challenges for satellite developers, the L-Series helps ease supply chain constraints while reducing budget pressure. Many timing solutions qualified for space environments have extended lead times and significant procurement costs. The L-Series is designed to provide a more accessible alternative, with many configurations available from stock or with lead times of less than 20 weeks. Additionally, the L-Series oscillators may lower overall program costs by reducing the need for the component pedigree, documentation requirements and inspection overhead that are typically associated with traditional high-reliability space-grade timing products.

“Satellite developers should not have to choose between dependable precision timing and the cost and schedule requirements of their mission,” said Randy Brudzinski, corporate vice president of Microchip’s frequency and time systems business unit. “Our L-Series oscillators bring together the performance, radiation tolerance and supply availability our customers need to confidently deploy their New Space applications using a precision timing solution that helps reduce both schedule and mission risk.”

The new LX-820 is available in a compact 3.2 mm × 2.5 mm surface-mount package and is designed to operate across a wide temperature range from -55°C to 125°C. The rugged device is engineered to meet MIL-PRF-55310 Level B and provides ±100 ppm performance. Additionally, the LX-820 supports CMOS output frequencies from 1.25 MHz to 135 MHz and low-voltage differential signaling (LVDS) output frequencies from 100 MHz to 250 MHz.

Modern satellite systems rely on highly accurate timing references to support communications, navigation, Earth observation, mapping and emerging lunar missions. As these applications can have different timing requirements, Microchip’s L-Series encompasses crystal oscillators (XOs), temperature-compensated crystal oscillators (TCXOs), oven-controlled crystal oscillators (OCXOs) and a pulse-per-second (PPS) disciplined oscillator. These products allow developers to use compact XOs where size and broad frequency coverage are priorities, TCXOs where tighter temperature stability and lower power are needed, OCXOs for more demanding stability and phase-noise requirements, and a disciplined oscillator where PPS synchronization and holdovers are required.

Microchip offers an extensive portfolio of clock and timing systems, ranging from miniature component oscillators, to small plug-in timing server cards, to atomic clocks and multi-rack time scale systems. As a primary contributor to the world’s time, Microchip’s timing solutions are trusted, reliable and resilient. For more information, visit Microchip’s clock and timing solutions webpage.

Pricing and Availability

The LX-820 Crystal Oscillator and other L-Series oscillators are now available in production quantities. For additional information and to purchase, contact a Microchip sales representative or authorized worldwide distributor.

Resources

High-res images available through Flickr or editorial contact (feel free to publish):

• Application image: www.flickr.com/photos/microchiptechnology/55522445284/sizes/l

About Microchip Technology:
Microchip Technology Inc. is a broadline supplier of semiconductors committed to making innovative design easier through total system solutions that address critical challenges at the intersection of emerging technologies and durable end markets. Its easy-to-use development tools and comprehensive product portfolio supports customers throughout the design process, from concept to completion. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support and delivers solutions across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. For more information, visit the Microchip website at www.microchip.com.

Note: The Microchip name and logo and the Microchip logo are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. All other trademarks mentioned herein are the property of their respective companies.

Editorial Contact:
Kim Dutton
kim.dutton@microchip.com

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — Teads Holding Co. (NASDAQ: TEAD), announced today that the company will release its third quarter 2026 results before the market opens on Thursday, November 5, 2026, followed by a conference call at 8:30 a.m. (Eastern Time) that same day to discuss the company’s results and business outlook.

The conference call can be accessed live over the phone by dialing 1-800-717-1738 or for international callers,1-646-307-1865. A replay will be available three hours after the call and can be accessed by dialing 1-877-660-6853, or for international callers, 1-201-612-7415. The passcode for the live call and replay is 13763331. The replay will be available until November 19, 2026.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company’s website at https://investors.teads.com/. The online replay will be available for a limited time shortly following the call.

About Teads

Teads Holding Co. (“Teads”) (Nasdaq: TEAD) is a leading omnichannel advertising platform focused on driving outcomes for brand and performance advertisers across screens. With a focus on meaningful business outcomes for full funnel objectives, Teads drives value by leveraging predictive AI technology to connect quality media, beautiful brand creative, and context-driven addressability and measurement. Teads is directly partnered with more than 10,000 publishers and 20,000 advertisers globally. The company is headquartered in New York, New York, with a global team of around 1,700 people in 30+ countries.

For more information, visit www.teads.com.

Media Contact

press@teads.com

Investor Relations Contact

IR@teads.com

(332) 205-8999

Delivered Record First Quarter Operating Income, Up 28 Percent Year-Over-Year
Strong Results Reflect Productivity Improvements, Mix Optimization and Benefits from Pricing Actions
Realized Adjusted Operating Margin in Specialty Alloys Operations Segment of 37.7 Percent
Demand Accelerating in Commercial Aerospace Supply Chain, Resulting in Increased Bookings

PHILADELPHIA, Oct. 22, 2026 (GLOBE NEWSWIRE) — Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced financial results for the fiscal first quarter ended September 30, 2026. For the quarter, the Company reported operating income of $196.4 million and earnings per diluted share of $3.25.

First Quarter Fiscal Year 2027 Highlights

• Delivered $196.4 million of operating income, up 28 percent year-over-year and down 5 percent sequentially
• Sequential performance reflects productivity improvements, mix management and benefits from pricing actions, offset by planned downtime for preventive maintenance activities
• Generated Specialty Alloys Operations (“SAO”) segment operating income of $216.3 million, up 27 percent year-over-year and down 6 percent sequentially
• Delivered adjusted operating margin of 37.7 percent in the SAO segment, up from 32.0 percent in the prior year first quarter and in line with 37.8 percent in the fourth quarter of fiscal year 2026
• Strong bookings for Commercial Aerospace, led by aerospace structural and distribution sub-markets which saw bookings increase 23 percent sequentially and 49 percent year-over-year
• Executed $133.9 million in share repurchases against repurchase programs; announced additional $1.0 billion share repurchase program in August 2026
• Realized earnings per diluted share of $3.25 in the quarter
• Generated $52.8 million of cash from operating activities

Outlook

• For the second quarter of fiscal year 2027, anticipate between $192 million to $197 million in operating income
• Maintain fiscal year 2027 operating income outlook in the range of $850 million to $880 million, representing a 21 percent to 25 percent increase over fiscal year 2026 operating income
• Well positioned for continued growth beyond fiscal year 2027 with strong market demand for our broad portfolio of specialized solutions, ongoing productivity improvements, product mix optimization, and realization of pricing actions

“Carpenter Technology delivered another strong quarter, generating $196.4 million of operating income in the first quarter of fiscal year 2027,” said Tony R. Thene, Chairman, President and CEO of Carpenter Technology. “This was the most profitable first quarter in the Company’s history, up 28 percent over the first quarter of fiscal year 2026, establishing a strong foundation for the rest of the fiscal year. The results, driven by productivity improvements, mix management and the benefits of pricing actions, were impressive for a quarter with increased preventive maintenance activities. Specifically, the SAO segment delivered $216.3 million of operating income and adjusted operating margin of 37.7 percent in the quarter, both significant increases over the previous year first quarter.”

“Notably, in the current quarter we saw a step up in demand, especially in the commercial aerospace supply chain. Customers in the aerospace structural and distribution sub-markets have increasing confidence in the industry’s ability to ramp and our engine customers are increasing activity to support new builds and elevated MRO activity. As a result, we saw increased sequential bookings across the commercial aerospace sub-markets, with the aerospace structural and distribution sub-markets leading the way. Further, in the strong demand environment, pricing continues to strengthen across our business.”

“We maintain our recently communicated fiscal year 2027 operating income outlook of $850 million to $880 million and our fiscal year 2029 operating income target of $1.2 billion to $1.3 billion which reflects the accelerating demand environment, continued benefits of pricing actions and the expected contribution from our brownfield capacity expansion project.”

“In addition, we are currently working on specific actions and projects to exceed our operating income targets for fiscal year 2027 and fiscal year 2029. With macro trends so strong and accelerating, we see additional upside to demand, pricing opportunity and productivity improvement that could drive our operating income even higher.”

“Altogether, we believe we have a compelling value creation story. We are delivering record results today with strong operating margins and levers to expand margins further, we see accelerating demand across our key end-use markets, and we continue to benefit from pricing actions. As a result, we have a clear path to significant earnings growth over the next several years, and we are positioned to create substantial long-term value for our shareholders.”

Financial Highlights

		Q1				Q4			Q1
($ in millions, except per share amounts)		FY2027				FY2026			FY2026
Net sales		$	798.2			$	851.0		$	733.7
Net sales excluding surcharge (a)		$	634.8			$	679.7		$	603.1
Operating income		$	196.4			$	206.9		$	153.3
Net income		$	162.5			$	162.4		$	122.5
Earnings per diluted share		$	3.25			$	3.23		$	2.43
Net cash provided from operating activities		$	52.8			$	240.1		$	39.2
Free cash flow (a)		$	(24.8	)		$	155.0		$	(3.4	)
(a) Non-GAAP financial measures explained in the attached tables

Net sales for the first quarter of fiscal year 2027 were $798.2 million, compared with $733.7 million in the first quarter of fiscal year 2026, an increase of $64.5 million (or 9 percent). Net sales excluding surcharge were $634.8 million for the current quarter, an increase of $31.7 million (or 5 percent) from the same period a year ago.

Operating income for the first quarter of fiscal year 2027 was $196.4 million compared to operating income of $153.3 million in the prior year period. Earnings per diluted share for the first quarter of fiscal year 2027 was $3.25 compared to earnings of $2.43 per diluted share in the prior year first quarter.

Cash provided from operating activities in the first quarter of fiscal year 2027 was $52.8 million, compared to $39.2 million in the same quarter last year. Free cash flow in the first quarter of fiscal year 2027 was negative $24.8 million, compared to negative $3.4 million in the same quarter last year. The increase in operating cash flow in the first quarter of fiscal year 2027 reflects higher earnings partially offset by changes in working capital, primarily inventory, compared to the same quarter last year. The unfavorable change in free cash flow reflects increased capital expenditures compared to the prior year period, namely from the brownfield expansion. Capital expenditures were $77.7 million in the first quarter of fiscal year 2027 compared to $42.6 million in the same quarter last year.

During the quarter ended September 30, 2026, the Company purchased 241,924 shares of its common stock on the open market for an aggregate of $133.9 million. As of September 30, 2026, $985.0 million remains available for future purchases under the $1.0 billion share repurchase program authorized in August 2026.

Total liquidity, including cash and available revolver balance, was $658.6 million at the end of the first quarter of fiscal year 2027. This consisted of $159.5 million of cash and $499.1 million of available borrowings under the Company’s Credit Facility.

Conference Call and Webcast Presentation

Carpenter Technology will host a conference call and webcast presentation today, October 22, 2026, at 10:00 a.m. ET, to discuss the financial results of operations for the first quarter of fiscal year 2027. Please dial +1 (833) 461-5787 for access to the live conference call. Access to the live webcast will be available at Carpenter Technology’s website (https://www.carpentertechnology.com), and a replay will soon be made available at https://www.carpentertechnology.com. Presentation materials used during this conference call will be available for viewing and download at https://www.carpentertechnology.com.

Non-GAAP Financial Measures

This press release includes discussions of financial measures that have not been determined in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). A reconciliation of the non-GAAP financial measures to their most directly comparable financial measures prepared in accordance with GAAP, accompanied by reasons why the Company believes the non-GAAP measures are important, are included in the attached schedules.

About Carpenter Technology

Carpenter Technology Corporation is a recognized leader in high-performance specialty alloy materials and process solutions for critical applications in the aerospace and defense, medical, energy, transportation, and industrial and consumer markets. Founded in 1889, Carpenter Technology has evolved to become a pioneer in premium specialty alloys including nickel, cobalt, and titanium and material process capabilities that solve our customers’ current and future material challenges. More information about Carpenter Technology can be found at https://www.carpentertechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding guidance, outlook, targets, objectives, future operating performance, cash generation, capital allocation, market conditions and strategic initiatives. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from those projected, anticipated, expected or implied. The most significant of these uncertainties are described in Carpenter Technology’s filings with the Securities and Exchange Commission, including its report on Form 10-K for the fiscal year ended June 30, 2026, and the exhibits attached to that filing. They include but are not limited to: (1) the cyclical nature of the specialty materials business and certain end-use markets, including aerospace, defense, medical, energy, transportation, industrial and consumer, or other influences on Carpenter Technology’s business such as new competitors, the consolidation of competitors, customers, and suppliers or the transfer of manufacturing capacity from the United States to foreign countries; (2) the ability of Carpenter Technology to achieve cash generation, growth, earnings, profitability, operating income, cost savings and reductions, qualifications, productivity improvements or process changes; (3) the ability to recoup increases in the cost of energy, raw materials, freight or other factors; (4) domestic and foreign excess manufacturing capacity for certain metals; (5) fluctuations in currency exchange and interest rates; (6) the effect of government trade actions, including tariffs; (7) the valuation of the assets and liabilities in Carpenter Technology’s pension trusts and the accounting for pension plans; (8) possible labor disputes or work stoppages; (9) the potential that our customers may substitute alternate materials or adopt different manufacturing practices that replace or limit the suitability of our products; (10) the ability to successfully acquire and integrate acquisitions; (11) the availability of credit facilities to Carpenter Technology, its customers or other members of the supply chain; (12) the ability to obtain energy or raw materials, especially from suppliers located in countries that may be subject to unstable political or economic conditions; (13) Carpenter Technology’s manufacturing processes are dependent upon highly specialized equipment located primarily in facilities in Reading and Latrobe, Pennsylvania and Athens, Alabama for which there may be limited alternatives if there are significant equipment failures or a catastrophic event; (14) the ability to hire and retain a qualified workforce and key personnel, including members of the executive management team, management, metallurgists and other skilled personnel; (15) fluctuations in oil and gas prices and production; (16) the impact of potential cybersecurity incidents, ransomware attacks, malicious AI usage, operational technology disruptions, information technology failures, data security breaches and failures of third-party technology service providers; (17) the ability of suppliers, logistics providers and other supply-chain participants to meet obligations due to capacity constraints, transportation disruptions, energy shortages, geopolitical events, labor shortages or other factors; (18) the ability to meet increased demand, production targets or commitments; (19) the ability to manage the impacts of natural disasters, climate change, pandemics and outbreaks of contagious diseases and other adverse public health developments; (20) geopolitical, economic, regulatory and security risks relating to our global business, including international conflicts, military actions, diplomatic tensions, trade restrictions, sanctions, disruptions to transportation corridors and shipping routes and changes in U.S. and foreign trade, tax and regulatory requirements; (21) challenges affecting the commercial aviation industry or key participants; (22) the consequences of the announcement, maintenance or use of Carpenter Technology’s share repurchase program; and (23) the ability to successfully execute major capital projects and brownfield expansion initiatives, including achieving expected costs, schedules, capacity additions, productivity improvements and returns on investment. Any of these factors could have an adverse and/or fluctuating effect on Carpenter Technology’s results of operations. The forward-looking statements in this document are intended to be subject to the safe harbor protection provided by Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. We caution you not to place undue reliance on forward-looking statements, which speak only as of the date of this press release or as of the dates otherwise indicated in such forward-looking statements. Carpenter Technology undertakes no obligation to update or revise any forward-looking statements.

PRELIMINARY CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data) (Unaudited)
		Three Months Ended
		September 30,
			2026				2025
NET SALES		$	798.2			$	733.7
Cost of sales			541.9				517.3
Gross profit			256.3				216.4
Selling, general and administrative expenses			59.9				63.1
Operating income			196.4				153.3
Interest expense, net			7.1				11.5
Other income, net			(3.1	)			(3.0	)
Income before income taxes			192.4				144.8
Income tax expense			29.9				22.3
NET INCOME		$	162.5			$	122.5
EARNINGS PER COMMON SHARE:
Basic		$	3.26			$	2.45
Diluted		$	3.25			$	2.43
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic			49.8				50.1
Diluted			50.0				50.4
Cash dividends per common share		$	0.20			$	0.20

PRELIMINARY CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions) (Unaudited)
		Three Months Ended
		September 30,
			2026				2025
OPERATING ACTIVITIES
Net income		$	162.5			$	122.5
Adjustments to reconcile net income to net cash provided from operating activities:
Depreciation and amortization			36.6				36.0
Deferred income taxes			11.6				5.8
Net pension expense			1.5				3.6
Share-based compensation expense			6.4				5.6
Net loss on disposals of property, plant and equipment			0.3				0.3
Changes in working capital and other:
Accounts receivable			(18.7	)			(36.2	)
Inventories			(61.6	)			15.6
Other current assets			(13.3	)			7.7
Accounts payable			24.1				(27.0	)
Accrued liabilities			(88.5	)			(85.9	)
Pension plan contributions			(8.6	)			(5.9	)
Other postretirement plan contributions			(0.7	)			(0.9	)
Other, net			1.2				(2.0	)
Net cash provided from operating activities			52.8				39.2
INVESTING ACTIVITIES
Purchases of property, plant, equipment and software			(77.7	)			(42.6	)
Proceeds from disposals of property, plant and equipment			0.1				—
Net cash used for investing activities			(77.6	)			(42.6	)
FINANCING ACTIVITIES
Dividends paid			(9.9	)			(10.1	)
Purchases of treasury stock			(133.9	)			(49.1	)
Proceeds from stock options exercised			0.4				0.5
Withholding tax payments on share-based compensation awards			(65.2	)			(45.5	)
Net cash used for financing activities			(208.6	)			(104.2	)
Effect of exchange rate changes on cash and cash equivalents			(0.4	)			0.1
DECREASE IN CASH AND CASH EQUIVALENTS			(233.8	)			(107.5	)
Cash and cash equivalents at beginning of year			393.3				315.5
Cash and cash equivalents at end of period		$	159.5			$	208.0

PRELIMINARY CONSOLIDATED BALANCE SHEETS (in millions) (Unaudited)
		September 30,				June 30,
			2026				2026
ASSETS
Current assets:
Cash and cash equivalents		$	159.5			$	393.3
Accounts receivable, net			722.2				701.9
Inventories			884.4				822.9
Other current assets			76.0				63.1
Total current assets			1,842.1				1,981.2
Property, plant, equipment and software, net			1,538.0				1,487.9
Goodwill			227.3				227.3
Other intangibles, net			2.4				3.9
Deferred income taxes			5.5				5.5
Other assets			129.4				132.5
Total assets		$	3,744.7			$	3,838.3
LIABILITIES
Current liabilities:
Accounts payable		$	345.3			$	313.4
Accrued liabilities			122.2				206.6
Total current liabilities			467.5				520.0
Long-term debt			691.0				690.7
Accrued pension liabilities			82.4				89.6
Accrued postretirement benefits			21.7				22.2
Deferred income taxes			207.4				196.9
Other liabilities			91.9				91.3
Total liabilities			1,561.9				1,610.7
STOCKHOLDERS’ EQUITY
Common stock			286.8				286.8
Capital in excess of par value			341.8				357.1
Reinvested earnings			2,352.3				2,199.7
Common stock in treasury, at cost			(772.5	)			(595.6	)
Accumulated other comprehensive loss			(25.6	)			(20.4	)
Total stockholders’ equity			2,182.8				2,227.6
Total liabilities and stockholders’ equity		$	3,744.7			$	3,838.3

PRELIMINARY SEGMENT FINANCIAL DATA (in millions) (Unaudited)
		Three Months Ended
		September 30,
			2026				2025
Net sales:
Specialty Alloys Operations
Net sales excluding surcharge		$	573.5			$	533.9
Surcharge			156.9				125.7
Specialty Alloys Operations net sales			730.4				659.6
Performance Engineered Products
Net sales excluding surcharge			83.0				87.2
Surcharge			8.1				6.4
Performance Engineered Products net sales			91.1				93.6
Intersegment
Net sales excluding surcharge			(21.7	)			(18.0	)
Surcharge			(1.6	)			(1.5	)
Intersegment net sales			(23.3	)			(19.5	)
Consolidated net sales		$	798.2			$	733.7
Operating income (loss):
Specialty Alloys Operations		$	216.3			$	170.7
Performance Engineered Products			7.3				9.4
Corporate			(26.1	)			(26.6	)
Intersegment			(1.1	)			(0.2	)
Consolidated operating income		$	196.4			$	153.3

The Company has two reportable segments, Specialty Alloys Operations (“SAO”) and Performance Engineered Products (“PEP”).

The SAO segment is comprised of Carpenter’s major premium alloy and stainless steel manufacturing operations. This includes operations performed at mills primarily in Reading and Latrobe, Pennsylvania and surrounding areas as well as South Carolina and Alabama.

The PEP segment is comprised of the Company’s differentiated operations. This segment includes the Dynamet titanium business, the Carpenter Additive business and the Latrobe and Mexico distribution businesses. The businesses in the PEP segment are managed with an entrepreneurial structure to promote flexibility and agility to quickly respond to market dynamics. It is our belief this model will ultimately drive overall revenue and profit growth.

Corporate costs are comprised of executive and director compensation, and other corporate facilities and administrative expenses not allocated to the segments. Also included are items that management considers not representative of ongoing operations and other specifically-identified income or expense items.

The service cost component of net pension expense, which represents the estimated cost of future pension liabilities earned associated with active employees, is included in the operating results of the business segments. The residual net pension expense is included in other income, net, and is comprised of the expected return on plan assets, interest costs on the projected benefit obligations of the plans, amortization of actuarial gains and losses and prior service costs.

PRELIMINARY NON-GAAP FINANCIAL MEASURES (in millions, except per share data) (Unaudited)
ADJUSTED OPERATING MARGIN EXCLUDING SURCHARGE REVENUE		Three Months Ended
		September 30,
			2026				2025
Net sales		$	798.2			$	733.7
Less: surcharge revenue			163.4				130.6
Net sales excluding surcharge revenue		$	634.8			$	603.1
Operating income		$	196.4			$	153.3
Operating margin			24.6	%			20.9	%
Adjusted operating margin excluding surcharge revenue			30.9	%			25.4	%

ADJUSTED SEGMENT OPERATING MARGIN EXCLUDING SURCHARGE REVENUE		Three Months Ended
		September 30,
			2026				2025
Specialty Alloys Operations
Net sales		$	730.4			$	659.6
Less: surcharge revenue			156.9				125.7
Net sales excluding surcharge revenue		$	573.5			$	533.9
Operating income		$	216.3			$	170.7
Operating margin			29.6	%			25.9	%
Adjusted operating margin excluding surcharge revenue			37.7	%			32.0	%

ADJUSTED SEGMENT OPERATING MARGIN EXCLUDING SURCHARGE REVENUE		Three Months Ended
		September 30,
			2026				2025
Performance Engineered Products
Net sales		$	91.1			$	93.6
Less: surcharge revenue			8.1				6.4
Net sales excluding surcharge revenue		$	83.0			$	87.2
Operating income		$	7.3			$	9.4
Operating margin			8.0	%			10.0	%
Adjusted operating margin excluding surcharge revenue			8.8	%			10.8	%

Management believes that removing the impact of raw material surcharge from operating margin provides a more consistent basis for comparing results of operations from period to period, thereby permitting management to evaluate performance and investors to make decisions based on the ongoing operations of the Company. Management uses its results excluding this amount to evaluate its operating performance and to discuss its business with investment institutions, the Company’s board of directors and others.

		Three Months Ended
		September 30,
FREE CASH FLOW			2026				2025
Net cash provided from operating activities		$	52.8			$	39.2
Purchases of property, plant, equipment and software			(77.7	)			(42.6	)
Proceeds from disposals of property, plant and equipment			0.1				—
Free cash flow		$	(24.8	)		$	(3.4	)

Management believes that the presentation of free cash flow provides useful information to investors regarding our financial condition because it is a measure of cash generated which management evaluates for alternative uses. It is management’s current intention to use excess cash to fund investments in capital equipment, acquisition opportunities and consistent dividend payments. Additionally, we will discretionarily use excess cash for a share repurchase program up to $1.0 billion of our outstanding common stock. Free cash flow is not a U.S. GAAP financial measure and should not be considered in isolation of, or as a substitute for, cash flows calculated in accordance with U.S. GAAP.

PRELIMINARY SUPPLEMENTAL SCHEDULE (in millions) (Unaudited)
		Three Months Ended
		September 30,
NET SALES BY END-USE MARKET		2026			2025
End-Use Market Excluding Surcharge Revenue:
Aerospace and Defense		$	425.4		$	388.3
Medical			51.7			61.6
Energy			32.9			42.5
Transportation			19.8			17.9
Industrial and Consumer			83.2			75.0
Distribution			21.8			17.8
Total net sales excluding surcharge revenue			634.8			603.1
Surcharge revenue			163.4			130.6
Total net sales		$	798.2		$	733.7

Investor Inquiries:		Media Inquiries:
John Huyette		Heather Beardsley
+1 610-208-2061		+1 610-208-2278
jhuyette@cartech.com		hbeardsley@cartech.com

Acquisition Expands Climb’s European Platform and Deepens Strategic Vendor Relationships

Transaction Expected to be Accretive to Earnings and Adjusted EBITDA

EATONTOWN, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) — Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb” or the “Company”), a value-added global IT channel company providing unique sales and distribution solutions for innovative technology vendors, has completed the acquisition of NeoVAD, a France-based value-added IT distributor focused on cybersecurity, cloud services and virtualization, serving reseller partners across the French market, for an aggregate purchase price of approximately €16.0 million ($18.0 million¹).

NeoVAD brings its established presence in France to Climb with approximately 300 active resellers and vendor relationships including Cato Networks, DataCore and Netwrix, among others. For its fiscal year ended December 31, 2025, NeoVAD generated EBITDA of approximately €2.2 million² ($2.5 million)³, which was up 487% from approximately €378,000² ($427,000)³ the prior fiscal year.

Management Commentary

“NeoVAD is a strong fit with our strategy to continue expanding Climb’s scale and capabilities across Europe,” said Climb CEO Dale Foster. “The acquisition adds meaningful reach in France while strengthening several important vendor relationships and creating opportunities to bring more of Climb’s portfolio to NeoVAD’s reseller network. At the same time, NeoVAD’s established position in France can help us build greater depth with vendors including Cato Networks, DataCore and Netwrix across our broader platform. We also see a meaningful opportunity to expand our Microsoft distribution business by pairing our existing EMEA capabilities with NeoVAD’s local training and technical support expertise. We expect this acquisition to be accretive to earnings and adjusted EBITDA, while NeoVAD’s stronger margin profile further supports our profitability objectives and expands our European platform for continued growth.”

Commenting on the acquisition, NeoVAD Founder and CEO Jérôme Boulon stated: “For more than a decade, we have built NeoVAD around a focused portfolio of cybersecurity, cloud and virtualization solutions and a high-touch model designed to help resellers successfully bring those technologies to market. Climb shares our focus on specialized, value-added distribution and brings broader scale and capabilities that can help us build on what we have established in France. We see significant opportunity to expand the solutions we bring to our reseller partners while creating additional opportunities for our vendors across Climb’s European platform.”

Additional information can be found in Climb’s Current Report on Form 8-K to be filed with the Securities and Exchange Commission on October 22, 2026.

About Climb Global Solutions

Climb Global Solutions, Inc. (NASDAQ:CLMB) is a value-added global IT distribution and solutions company specializing in emerging and innovative technologies. Climb operates across the U.S., Canada and Europe through multiple business units, including Climb Channel Solutions, Grey Matter and Climb Global Services. The Company provides IT distribution and solutions for companies in the Security, Data Management, Connectivity, Storage & HCI, Virtualization & Cloud, and Software & ALM industries.

Additional information can be found by visiting www.climbglobalsolutions.com.

About NeoVAD

NeoVAD is a value-added IT distributor headquartered in Boulogne-Billancourt, France, serving reseller partners across the French market. The company specializes in cybersecurity, cloud services and virtualization solutions and maintains relationships with technology vendors including Cato Networks, DataCore and Netwrix, among others. NeoVAD operates a fully indirect, two-tier distribution model supporting approximately 300 active resellers, integrators and MSPs. Through its high-touch approach, the company provides presales, technical training, marketing and demand-generation support designed to help partners successfully bring vendor solutions to market.

Non-GAAP Financial Measures

Climb uses non-GAAP financial measures, including adjusted EBITDA, as supplemental measures of the performance of the Company’s business. Use of these financial measures has limitations, and you should not consider them in isolation or use them as substitutes for analysis of Climb’s financial results under generally accepted accounting principles in the United States of America (“U.S. GAAP”).

Forward-Looking Statements

The statements in this release, other than statements of historical fact, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are intended to come within the safe harbor protection provided by those sections. These forward-looking statements are subject to certain risks and uncertainties. Many of the forward-looking statements may be identified by words such as ”looking ahead,” “believes,” “expects,” “intends,” “anticipates,” “plans,” “estimates,” “projects,” “forecasts,” “should,” “could,” “would,” “will,” “confident,” “may,” “can,” “potential,” “possible,” “proposed,” “in process,” “under construction,” “in development,” “opportunity,” “target,” “outlook,” “maintain,” “continue,” “goal,” “aim,” “commit,” or similar expressions, or when we discuss our priorities, strategy, goals, vision, mission, opportunities, projections, intentions or expectations. In this press release, the forward-looking statements relate to, among other things, declaring and reaffirming our strategic goals, future operating results, and the effects and potential benefits of strategic acquisitions on our business. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include, without limitation, our ability to recognize the anticipated benefits of the acquisitions of NeoVAD and interworks.cloud, the possibility that the anticipated earnings and adjusted EBITDA accretion, synergies, margin improvements and other strategic benefits of the NeoVAD acquisition may not be realized within the expected timeframe or at all; difficulties integrating NeoVAD’s operations, employees, systems and distribution activities; the Company’s ability to retain key NeoVAD personnel, resellers and vendor relationships; and changes in the commercial terms, availability or performance of material vendor arrangements; the continued acceptance of the Company’s distribution channel by vendors and customers, the timely availability and acceptance of new products, product mix, market conditions, competitive pricing pressures, the successful integration of acquisitions, contribution of key vendor relationships and support programs, inflation, import and export tariffs, the successful integration artificial intelligence tools, interest rate risk and impact thereof, as well as factors that affect the software industry in general. The forward looking statements contained herein are also subject generally to other risks and uncertainties that are described in the section entitled “Risk Factors” contained in Item 1A. of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and from time to time in the Company’s filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of this release, except as required by law.

Company Contact

Matthew Sullivan
Chief Financial Officer
(732) 847-2451
MatthewS@ClimbCS.com

Investor Relations Contact

Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
CLMB@elevate-ir.com

---

¹ Amount converted from EUR to USD based on an exchange rate of €1 = $1.12 as of 10/21/26.
² Amount derived from the internal financial statements prepared by management of NeoVAD and may not be comparable to Climb’s non-GAAP measures.
³ Amount converted from EUR to USD based on average exchange rate during the 12-month period ended December 2025 (€1 = $1.13).

SCOTTSDALE, Ariz., Oct. 22, 2026 (GLOBE NEWSWIRE) — WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary flexible space solutions, today announced that it will release its third quarter 2026 financial results on November 5, 2026, after market close.

The Company’s management team will host a conference call and webcast on November 5, 2026, at 5:30 p.m. EST to discuss the Company’s results.

To access the live call by phone, use the following link by clicking here to obtain registration details.

You will be provided with dial-in details after registering. To avoid delays, we recommend that participants dial into the conference call 15 minutes ahead of the scheduled start time. A live webcast will also be accessible via the “Events & Presentations” section of the Company’s website www.investors.willscot.com. An archived version of the webcast will be available for 12 months following the call.

The Company also announced today that it will participate in the following investor conferences:

• Baird Global Industrial Conference
  Date: November 10-11, 2026
  Location: Chicago, Illinois

• Bank of America Leveraged Finance Conference
  Date: December 1, 2026
  Location: Boca Raton, Florida

• UBS Global Industrials and Transportation Conference
  Date: December 2, 2026
  Location: Manalapan, Florida

• Oppenheimer Winter Industrial Summit
  Date: December 8-9, 2026
  Location: Virtual

Portfolio managers and analysts who wish to request an in-person meeting should contact their sales representative at the sponsoring firm. Please check the “Events & Presentations” section at www.investors.willscot.com for updated details, including timing and links for potential webcasting.

About WillScot

WillScot (Nasdaq: WSC) is a leading provider of innovative turnkey space solutions in North America, helping customers keep projects moving and operations running. The Company partners with critical industries including construction, manufacturing, healthcare, government, energy and education to deliver the right solutions coupled with a high level of customer service. WillScot’s comprehensive portfolio of products – including modular complexes, dry and cold storage containers, blast-resistant buildings, clearspan industrial structures, fencing, and add-on furnishings and equipment – is customizable and flexible to support any project need. Headquartered in Scottsdale, Ariz., WillScot operates from a network of approximately 240 branch locations in the U.S., Canada, and Mexico.

Additional information can be found on the company’s website at www.willscot.com.

Contact Information

Investor inquiries:
Charlie Wohlhuter
Investors@willscot.com

Media inquiries:
Juliana Welling
Media@willscot.com 

Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associated Swelling, and Favorable Tolerability

MIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapies for neurologic, inflammatory and metabolic disorders, today announced positive results from a 21-day preclinical proof-of-concept study evaluating oral MIRA-55 in a validated model of chronic inflammatory pain. The results support the continued advancement of MIRA-55 toward an Investigational New Drug (IND) submission.

The study demonstrated that once-daily oral MIRA-55 significantly reduced both mechanical and thermal pain hypersensitivity (p < 0.001 versus vehicle) as from the lowest dose used. MIRA-55 achieved pain-relieving effects comparable in magnitude to celecoxib (Celebrex®), a widely prescribed medication for pain and inflammation, at the higher doses evaluated.

Importantly, the effects were maintained throughout the three-week study without evidence of tolerance. MIRA-55 also reduced inflammation-associated swelling and was well tolerated, with no adverse clinical signs observed during repeated daily administration.

These findings build on MIRA’s earlier preclinical studies, including previously reported results demonstrating that oral MIRA-55 normalized pain responses and reduced inflammation in an acute inflammatory pain model, outperforming injected morphine in that study. Together, these findings extend MIRA-55’s demonstrated preclinical analgesic activity into a model of persistent, chronic inflammatory pain, further supporting its development as a next-generation oral therapy designed to provide effective, long-term pain relief with an improved safety and tolerability profile.

Key Study Highlights

• Significant Pain Relief: MIRA-55 significantly reduced both mechanical and thermal pain hypersensitivity compared with vehicle-treated animals (p < 0.001).
• Comparable to Celebrex: MIRA-55 demonstrated pain-relieving effects comparable in magnitude to celecoxib, with no statistically significant differences observed between those treatments.
• Sustained Efficacy Without Observed Tolerance: Pain relief was maintained throughout the three-week study, with no observed decline in effectiveness during repeated daily dosing.
• Reduced Inflammation-Associated Swelling: MIRA-55 reduced paw swelling to a similar magnitude as the reduction observed with celecoxib.
• Consistent Results Across Both Sexes: MIRA-55 demonstrated comparable pain-relieving activity in male and female animals.
• Favorable Observed Tolerability: No adverse clinical signs or deaths were reported, and normal body-weight gain was maintained throughout the treatment period.

Advancing a Potential New Treatment for Chronic Inflammatory Pain
Chronic inflammatory pain remains a significant medical challenge, affecting patients with conditions such as arthritis and other inflammatory disorders. Existing treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs), can provide meaningful relief but may be limited by gastrointestinal, cardiovascular, renal, and other safety considerations, particularly with prolonged use.

MIRA-55 is a next-generation oral synthetic cannabinoid analog designed to modulate cannabinoid receptor pathways involved in pain signaling and inflammation. The program aims to deliver effective, sustained pain relief while minimizing unwanted effects associated with existing treatment approaches.

The U.S. Drug Enforcement Administration has determined that MIRA-55 is not a controlled substance.

“We are building a differentiated pain therapeutics franchise around two distinct programs addressing major unmet medical needs,” said Erez Aminov, Chairman and Chief Executive Officer of MIRA Pharmaceuticals. “With Ketamir-2 advancing toward Phase 2 clinical development for neuropathic pain and MIRA-55 progressing toward an IND for inflammatory pain, we are creating a pipeline of oral therapies targeting distinct but complementary areas of pain. We believe this strategy positions MIRA to create meaningful value for patients and shareholders as both programs advance through development.”

Study Design and Scientific Findings
The 21-day study was conducted by an independent contract research organization using the Complete Freund’s Adjuvant (CFA) model, a well-established preclinical model used to investigate persistent inflammatory pain.

The study included 72 male and female rats. MIRA-55 was administered orally once daily at multiple dose levels and evaluated against a vehicle control and celecoxib, an established prescription anti-inflammatory medication.

Researchers assessed mechanical and thermal pain sensitivity, inflammation-associated paw swelling, and general tolerability throughout the study.

MIRA-55 demonstrated statistically significant pain-relieving activity across all tested doses, with a dose-related response. Analgesic activity was observed following the first administration at the highest dose, while sustained effects were established within the first several days of treatment and maintained through the end of the study.

“One of the most encouraging aspects of these findings is the durability of the response,” said Itzchak Angel, Ph.D., Chief Scientific Advisor of MIRA Pharmaceuticals. “MIRA-55 demonstrated sustained analgesic activity over repeated low oral daily dosing, without evidence of tolerance, and produced consistent effects in both male and female animals. These results extend our earlier acute pain findings into a model of persistent inflammatory pain. The relationship between pain relief and reduced swelling also suggests potentially distinct contributions from pain-signaling and inflammatory pathways, which we are continuing to investigate.”

Supporting Advancement Toward Clinical Development
The positive findings provide additional proof-of-concept evidence supporting MIRA-55’s ongoing IND-enabling development program.

Additional tissue analyses are underway to evaluate inflammatory cytokines and molecular markers associated with pain signaling and neuroinflammation, including changes in the dorsal root ganglia and spinal cord. These analyses are expected to provide further insight into MIRA-55’s mechanism of action and help inform its continued development.

MIRA is advancing MIRA-55 toward a planned IND submission in the first quarter of 2027, subject to completion of the remaining required preclinical and regulatory activities.

About MIRA-55
MIRA-55 is an orally administered, next-generation synthetic cannabinoid analog being developed as a potential treatment for inflammatory pain. The compound is designed to modulate cannabinoid receptor pathways involved in pain and inflammation while minimizing unwanted psychoactive effects.

Previous preclinical studies have demonstrated analgesic and anti-inflammatory activity, including pain normalization in comparison with morphine in an acute inflammatory pain model. More recent findings demonstrate sustained pain-relieving activity in a model of chronic inflammatory pain.

The U.S. Drug Enforcement Administration has determined that MIRA-55 is not a controlled substance. MIRA-55 remains in preclinical development, and its safety and efficacy in humans have not been established.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization prospects, market opportunity, and future development of MIRA-55, SKNY-1, Ketamir-2, and the Company’s other product candidates.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s current beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Investors are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings, available at www.sec.gov and in the Investors section of the Company’s website at www.mirapharmaceuticals.com. Forward-looking statements should be considered in light of these risks and uncertainties.

Investor and Media Contact
Krystina Quintana
MIRA Pharmaceuticals
info@mirapharma.com 
(786) 432-9792